Diagnostic Center | August 18, 2022
Sanofi updates on amcenestrant clinical development program
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Company appoints five new independent directors to reconstituted board
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
Subscribe To Our Newsletter & Stay Updated
